DiaSorin SpA
Carlo Rosa is Chief Executive Officer of DiaSorin Spa. Born in 1966, in 1990 he graduated in Chemistry cum Laude from the University of Torino.
Hired Sorin Biomedica Spa, a company belonging to FIAT Spa, he was moved to New York to work at the NY Public Health Research Institute on an innovative program to develop new diagnostic tools for Hepatitis C diagnosis. In 1992, he joined Inctar Corporation Inc in Minnesota where he held different positions in R&D and strategic Marketing. In 1998 he moved back to Europe where he got the position of VP Europe Strategic Marketing at DiaSorin Spa, back then just acquired by the American Standard Group, a large US conglomerate with interests in healthcare.
In 2000, with the support of Mr. Gustavo Denegri, he led a management buy out of DiaSorin Spa and became its CEO in 2006, right before the Company got listed at the Milan Stock Exchange.
In 2016 got appointed as deputy Vice Chairman of Assobiotec and since 2015 been part of the Board of Directors of the Istituto Italiano di Tecnologia (IIT) where he also serves as a member of the Strategic Committee.
This person is not in any offices
DiaSorin SpA
4 followers
DiaSorin SpA is an Italy-based company engaged in healthcare industry. The Company specializes in provision of developing, producing and commercializing reagent kits for the in vitro diagnostics. The Company develops and manufactures reagents for in vitro diagnostics and produces products for the fields of infectious disease, hepatitis, endocrinology, bone & mineral metabolism, cancer, brain injury, cardiac, therapeutic drug monitoring and autoimmunity. The Company's business activities are divided into two markets. The Immunodiagnostics market develops, produces and markets immunoreagent kits, which are based on three techniques: Chemiluminescence (CLIA), Colorimetry (ELISA) and Radioimmunometry (RIA). The Molecular Diagnostics market supplies end laboratories with an automated result to perform the three steps for the final diagnostic result, including nucleic acids extraction, amplification and diagnosis. It operates through ELISA immunodiagnostic business portfolio.